Fred Sanford Gorelick, MD
Henry J. and Joan W. Binder Professor of Medicine (Digestive Diseases) and of Cell BiologyCards
About
Titles
Henry J. and Joan W. Binder Professor of Medicine (Digestive Diseases) and of Cell Biology
Director Investigated Gastroenterology NIH T32, Internal Medicine; Deputy Director, MD-PhD Program
Biography
After completing medical school and internal medicine training at the University of Missouri, Dr. Gorelick trained at Yale in Gastroenterology. After his clinical training, he began basic science training with Dr. James Jamieson at Yale. During that period he described calcium-calmodulin dependent protein kinase II and subsequently worked with Dr. Paul Greengard (Rockefeller University) to examine the enzyme's mechanism of activation, a response critical to neuronal memory.
His later work has focused on the mechanisms of acute pancreatits and how digestive enzymes, such as trypsin, are activated within the pancreas during this disease. Dr. Gorelick sees patients with gastrointestinal diseases at the VAMC in West Haven, CT. He is also the Deputy Director for the Yale physician Scientist program and directs a year-long course for the group that links basic science to clinical disease. He has also been the Director of the Yale Program in Investigative Gastroenterology for over 10 years. His laboratory at the VA studies the molecular mechanisms related to acute pancreatitis with a goal of developing tools that prevent or lessen disease.
Appointments
Cell Biology
ProfessorFully JointDigestive Diseases
ProfessorFully Joint
Other Departments & Organizations
- Cell Biology
- Digestive Diseases
- Internal Medicine
- Investigative Medicine Program
- MD-PhD Program
- Membrane Traffic
- Molecular Cell Biology, Genetics and Development
- Molecular Medicine, Pharmacology, and Physiology
- Pancreatic Diseases Program
- Program in Translational Biomedicine (PTB)
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Ventures
Education & Training
- Visiting Scientist
- Rockefeller University (2018)
- Post Doctoral
- Yale University (1980)
- GI Fellow
- Yale University School of Medicine (1979)
- Resident
- University of Missouri (1976)
- MD
- University of Missouri (1973)
Board Certifications
Gastroenterology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1980
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1976
Research
Overview
We have found that activation of digestive enzymes in the pancreatic acinar cell takes place in a special cellular organelle that has features of both a lysosome and classic secretory vesicle. Our recent focus has turned to the role of the survival factor, renalase (RNLS), a protein discovered by Dr. Desir and co-workers at Yale that modulates acute injury and inflammation. RNLS may enhance cell survival by activating a plasma-membrane calcium pump. We have found that RNLS reduces the severity of acute experimental pancreatitis. We have also found that it can be a driver for select cancers, including pancreatic adenocarcinoma. Efforts are underway to develop RNLS agonists and antagonists for therapeutic use. We have also found that plasma levels of RNLS are dynamically regulated and might be useful biomarkers in the setting of inflammatory injury as well as select cancers. Finally, we believe that specific estrogen receptors might account for greater acute pancreatitis severity in young females and could be targeting therapeutically. We plan to pursue these studies using rodents models of pancreatitis, human acinar cells, and to collaborate with clinical investigators to examine these pathways in patients to examine the following issues.
1) The effects of renalase in models of acute acute pancreatitis
2) Regulation of plasma renalase levels during acute injury and the function of plasma renalase binding proteins
2) Renalase as a driver for pancreatic cancer and its function in pancreatic cancer precursor lesions
3) The potential of serum renalase levels to be biomarkers in pancreatic cancer that corresponds to tumor stage.
4) The role of estradiol and estrogen receptors in acute pancreatitis models.
Medical Subject Headings (MeSH)
Academic Achievements and Community Involvement
Links & Media
Media
News
- May 29, 2024
Renalase May Predict Post-ERCP Pancreatitis
- April 18, 2024
Acute Pancreatitis: Disease Cause and Therapeutic Approaches
- April 10, 2024
Dr. Lisa Korn Receives 2024 Dostanic Award
- September 06, 2022
Meet Yale Internal Medicine: Dennis Shung, MD, MHS, PhD